A detailed history of Cavalier Investments, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Cavalier Investments, LLC holds 11,837 shares of SAGE stock, worth $67,826. This represents 0.03% of its overall portfolio holdings.

Number of Shares
11,837
Previous 11,147 6.19%
Holding current value
$67,826
Previous $121,000 29.75%
% of portfolio
0.03%
Previous 0.04%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$7.02 - $13.08 $4,843 - $9,025
690 Added 6.19%
11,837 $85,000
Q2 2024

Aug 02, 2024

BUY
$10.58 - $17.9 $3,279 - $5,549
310 Added 2.86%
11,147 $121,000
Q1 2024

Apr 26, 2024

BUY
$18.62 - $26.95 $10,594 - $15,334
569 Added 5.54%
10,837 $203,000
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $4,104 - $5,342
240 Added 2.39%
10,268 $222,000
Q3 2023

Oct 23, 2023

BUY
$16.75 - $48.98 $5,845 - $17,094
349 Added 3.61%
10,028 $206,000
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $393,451 - $576,287
9,679 New
9,679 $455,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Cavalier Investments, LLC Portfolio

Follow Cavalier Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cavalier Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cavalier Investments, LLC with notifications on news.